Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pepcid AC

This article was originally published in The Tan Sheet

Executive Summary

Generic versions of market-leading H2 antagonist have yet to receive final approval, FDA says. Cheminor Drugs, Danbury Pharmacal and Teva Pharmaceuticals all have tentatively approved ANDAs for famotidine 10 mg; J&J/Merck product lost marketing exclusivity April 15. As first to receive tentative approval (on Oct. 15, 1998), Teva could be granted 180 days of private label exclusivity, although FDA's decision remains unmade. Leiner, Perrigo, PFI and Zenith Goldline also plan to introduce generic famotidine in 2001

You may also be interested in...



Perrigo Famotidine Approved With Six Month Exclusivity; Shipments Begin

Perrigo's private label famotidine 10 mg was approved by FDA May 31, ending a drawn out delay of the generic launch.

Perrigo Famotidine Approved With Six Month Exclusivity; Shipments Begin

Perrigo's private label famotidine 10 mg was approved by FDA May 31, ending a drawn out delay of the generic launch.

Perrigo Famotidine Approved With Six Month Exclusivity; Shipments Begin

Perrigo's private label famotidine 10 mg was approved by FDA May 31, ending a drawn out delay of the generic launch.

Topics

UsernamePublicRestriction

Register

PS092462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel